

Investor Relations | Hologic
Hologic to Host Investor Presentation at RSNA 2010

PR Newswire
BEDFORD

BEDFORD, Mass., Oct. 13, 2010 [/PRNewswire-FirstCall/](#) -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the Company will host a presentation for members of the investment community at the 2010 RSNA (Radiological Society of North America) trade show in Chicago, IL. RSNA is the world's largest medical meeting. For more information about RSNA, please visit <http://rsna2010.rsna.org/>.

Hologic's investor meeting will be held on Tuesday, November 30, 2010, at McCormick Place from 8:00 to 10:00 a.m. (Central Time) and will include a presentation by members of Hologic's management team.

Interested participants may listen to the call (listen mode only) by dialing 866-277-1182 or 617-597-5359, passcode 42874701 beginning at 7:50 a.m. (Central Time) and referencing the Hologic Investor Meeting. For those unable to participate in the live broadcast, a replay will be available two hours after the call ends through Friday, December 17, 2010 at 888-286-8010 or 617-801-6888, passcode 18488130.

Interested parties are invited to listen to a live audio webcast of Hologic's presentation on the investor section of the company's website at www.hologic.com/investor. An archive of the presentation will be available for replay following the event.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Contact:

Deborah Gordon
Vice President, Investor Relations
Hologic, Inc.
deborah.gordon@hologic.com
(781) 999-7716

SOURCE Hologic, Inc.